Latest Advances in Lung Cancer Research

AstraZeneca’s Imfinzi shows promise in treating aggressive small cell lung cancer, potentially offering a new, more effective treatment option for this hard-to-treat disease.

Cancer cases projected to rise 77% by 2050 due to aging populations, with low-income countries and lung cancer most affected, emphasizing prevention and global action.

Cancer death rates in the U.S. have dropped 33% since 1991, saving 3.8 million lives, but disparities and challenges in certain cancers remain.

Women’s lung cancer is often diagnosed late and treated less aggressively than men’s lung cancer, despite being the leading cause of cancer death among women.

Lung cancer rates are increasing among Asian American women, according to a new study published in the journal Cancer.

The FDA has approved amivantamab for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations.

This article reviews strategies for managing treatment resistance in advanced EGFR-mutated lung cancer, focusing on personalization, parsimony, and partnership.

Tepotinib, the first FDA-approved treatment for MET-mutated lung cancer, improves tumor shrinkage and survival.

FDA approves osimertinib plus chemo as first-line treatment for EGFR-mutated lung cancer, improving survival.

Weill Cornell Medicine scientists create a mouse model to study lung cancer’s transformation into deadly SCLC.

Researchers who conducted a large study published in the journal Chest report that reproductive factors, such as early age at menopause and first childbirth, are associated with an increased risk of lung cancer.

Actress and comedian Kate Micucci, revealed last month that she had been diagnosed and treated for lung cancer despite having “never” smoked cigarettes. Micucci’s diagnosis came as a surprise to her followers, especially considering she is a non-smoker. However, lung cancer among non-smokers happens more often than most people realize.